A study on whether fasting glucagon values affect the effect of DPP4 inhibitors on type 2 diabetic patients.

A study on whether fasting glucagon values affect the effect of DPP4 inhibitors on type 2 diabetic patients. - Differences in clinical effect of DPP4 inhibitors due to differences in fasting glucagon.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030698

Enrollment

Registered

2018-01-17

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes (insulin independent diabetes )

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Type 2 diabetes managed only by diet therapy and exercise therapy. 2. Type 2 diabetes who have undergone diabetes treatment with internal medicine but have not been treated with DPP-4 inhibitor or GLP-1 receptor agonist until now, or have undergone diabetes treatment with internal medicine, A case in which a DPP-4 inhibitor has been administered but the DPP-4 inhibitor has been discontinued and has been 6 months or more has passed. 3. A case corresponding to 1 and 2 above and HbA1 c <= 7.0%.

Exclusion criteria

Exclusion criteria: 1. Cases of contraindications described in the package insert of sitagliptin 2. Cases during administration of DPP-4 inhibitor containing sitagliptin. 3. Cases during GLP-1 receptor agonist administration. 4. Patients treated with insulin (also switching to DPP-4 inhibitors) 5. Treating acute diseases. 6. Cases of malignant tumor complication and its history. 7. A case with moderate or higher renal dysfunction (Japanese estimated creatinine clearance <50 ml/min). 8. Liver function disorder associated with either AST (GOT) >100 IU/dl or ALT (GPT) >100 IU/dl 9. Pregnant women or women who may be pregnant. 10. A lactating woman. 11. A Case difficult to confirm whose intention. 12. Cases of complication of endocrine disorder. 13. A cases who uses drugs known to have side effects causing glucose metabolism (steroid drugs,Interferon etc) . 14. History of abdominal surgery. 15. Patients with metabolic incontinence symptoms associated with diabetes such as dry mouth, polydipsia, polyuria, nocturnal urine, and weight loss. 16. Cases with geriatric syndrome (sarcopenia, cognitive decline, ADL lowering etc).

Design outcomes

Primary

Measure	Time frame
Verification of difference in blood glucose improving effect of DPP-4 inhibitor in cases of type 2 diabetes with high or low fasting glucagon value.	—

Countries

Japan

Contacts

Public ContactRaishi Ichikawa

Kitasato University School of Medicine Department of Endcrinology, Diabetes and Metabolism

raizo@med.kitasato-u.ac.jp0427788111

Outcome results